Meningitis

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award

Retrieved on: 
Friday, April 19, 2024

Fueled by an early interest in science as a child in South Africa -- in part due to a physician father – Klugman holds both a medical as well as a science doctorate degree from Wits University and was the first student in the school’s history to obtain them simultaneously. He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist. Klugman is widely known for his work on pneumonia, which still kills a child under five every 43 seconds, many in the world’s poorest countries. As the director of the pneumonia program at the Seattle-based Bill and Melinda Gates Foundation, Klugman orchestrates strategic initiatives aimed at reducing deaths from pneumonia, RSV, neonatal sepsis, and meningitis. He has authored hundreds of publications that have been cited over 50,000 times to date and has been elected to the National Academy of Medicine in the United States. Klugman is also a professor emeritus of global health at Atlanta’s Emory University.

Key Points: 
  • Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute.
  • He began his research career nearly five decades ago investigating the typhoid vaccine and has since distinguished himself as a formidable infectious diseases’ scientist.
  • His scientific achievements aside, Klugman has long championed the need for the world’s poorest children to have equitable access to vaccines.
  • Sabin’s Rising Star award was created in 2020 to encourage and recognize the next generation of vaccine and immunization leaders.

Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections

Retrieved on: 
Wednesday, April 17, 2024

The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.

Key Points: 
  • The study included a large cohort of more than 4,800 patients over seven years diagnosed at UCSF.
  • In addition, the study found mNGS provided a definitive diagnosis for nearly 1 in 3 immunocompromised patients.
  • Ultimately, Delve Neuro will enable more patients with potentially life-threatening neurological infections to benefit from faster, more comprehensive diagnoses.
  • Prior to joining Delve Bio, Mr. Field served as Chief Commercial Officer at Clear Labs and IDbyDNA (acquired by Illumina).

Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Retrieved on: 
Wednesday, April 3, 2024

Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Key Points: 


Orphan designation: (1R,2S) 6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-(1-naphthyl)-beta-phenyl-3-quinolineethanol bedaquiline Treatment of tuberculosis, 26/08/2005 Withdrawn

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Monday, March 4, 2024

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Antibiotic Drugs Market Analysis Report 2024: Surging Demand, Trends, and Forecasts 2019-2029 - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 29, 2024

The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Antibiotic Drugs Market (2024 Edition): Analysis By Drug Class (Cephalosporin, Penicillin, Macrolides, Fluoroquinolone, Others), Spectrum (Broad, Narrow), By Indication, By Region, By Country: Market Insights and Forecast (2019-2029)" report has been added to ResearchAndMarkets.com's offering.
  • The report meticulously evaluates the antibiotic drugs industry's landscape, emphasizing the key drug classes such as Cephalosporins, Penicillins, Macrolides, and Fluoroquinolones.
  • This investigation aligns with an increased emphasis on antibiotic stewardship and the urgent need for combating antibiotic resistance globally.
  • The Antibiotic Drugs Market report not only underscores the significant trends and growth drivers but also furnishes a detailed forecast, setting the stage for informed decision-making and strategic planning within the pharmaceutical sector.

THE AMERICAN SOCIETY FOR MENINGITIS PREVENTION (ASMP) LAUNCHES TO ADDRESS GROWING NEED FOR MENINGITIS PREVENTION EDUCATION IN THE UNITED STATES

Retrieved on: 
Thursday, March 7, 2024

FARMINGTON HILLS, Mich., March 7, 2024 /PRNewswire/ -- The American Society for Meningitis Prevention (ASMP) launched today to empower Americans to take action to prevent meningococcal meningitis, a life-threatening bacterial infection. Founded by Patti Wukovits and Alicia Stillman, two mothers who tragically lost their daughters to meningococcal meningitis, ASMP aims to raise awareness among adolescents, young adults, parents, healthcare providers, and policymakers about meningococcal meningitis and the critical role of comprehensive vaccination in preventing it.

Key Points: 
  • FARMINGTON HILLS, Mich., March 7, 2024 /PRNewswire/ -- The American Society for Meningitis Prevention (ASMP) launched today to empower Americans to take action to prevent meningococcal meningitis, a life-threatening bacterial infection.
  • To help protect against meningococcal meningitis, patients must be vaccinated against all five types of meningococcal bacteria most likely to cause meningococcal meningitis: A–B–C–W–Y.ii
    "Meningitis prevention education is more important in the U.S. today than ever.
  • Starting today, the American Society for Meningitis Prevention will replace the Meningitis B Action Project.
  • To learn more about the American Society for Meningitis Prevention, visit meningitisprevention.org .

QIAGEN expands business in Middle East with new regional headquarters and major projects

Retrieved on: 
Wednesday, January 3, 2024

“At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.

Key Points: 
  • “At QIAGEN, we believe that improving healthcare outcomes starts with a strong foundation of collaboration and innovation, and we are excited to play a crucial role in advancing health and well-being throughout the Middle East.
  • To accommodate its growing regional presence and customer needs, QIAGEN will inaugurate its new regional headquarters in Riyadh, Saudi Arabia, at the beginning of 2024.
  • This office will further strengthen the company’s commitment to the Middle East and improve its ability to serve clients in the area.
  • The CDC and WHO endorse the use of QuantiFERON-TB Gold Plus in all settings to combat the global TB epidemic.

Inventprise Completes Vaccination of Participants in a Phase 2 Dose Ranging Study of its 25 Valent Pneumococcal Vaccine Candidate

Retrieved on: 
Tuesday, January 2, 2024

Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.

Key Points: 
  • Biotechnology company Inventprise Inc. today announced the completion of vaccination in their Phase 2 dose ranging study of its 25-valent pneumococcal conjugate vaccine (IVT PCV-25) in young adults.
  • This Phase 2 study is an important step in the efforts to develop an affordable, expanded-coverage pneumococcal conjugate vaccine (PCV).
  • The Inventprise PCV includes 25 serotypes—expanding the potential to prevent several deadly and emerging serotypes not yet addressed by existing PCVs.
  • A Phase 2 study in older adults is also planned to take place in the second half of 2024.

RevBio Receives FDA Approval to Conduct a First-in-Human Clinical Trial for its Regenerative Bone Adhesive for Cranial Flap Fixation

Retrieved on: 
Friday, December 8, 2023

This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.

Key Points: 
  • This approval was largely predicated on the successful pivotal preclinical and surgeon handling testing conducted by the company.
  • As part of the surgical closure process, the cranial flap is secured back into place with plates and screws.
  • The kerf line, however, is typically not sealed, which compromises the ability of the flap to integrate with the surrounding bone.
  • “We are truly excited to move this project into the clinical phase of testing,” said Brian Hess, CEO and Founder of RevBio.

Katalin Karikó and Anne Schuchat Receive 2023 Fries Prize for Improving Health

Retrieved on: 
Sunday, November 12, 2023

ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.

Key Points: 
  • ATLANTA, Nov. 12, 2023 /PRNewswire/ -- Nobel Prize Winner Katalin Karikó, PhD, and former Centers for Disease Control and Prevention (CDC) Principal Deputy Director Anne Schuchat, MD (RADM, USPHS, RET), today received the 2023 Fries Prize for Improving Health.
  • The Fries Prize for Improving Health award was presented this morning at the American Public Health Association's (APHA) annual meeting, which is taking place in Atlanta.
  • The monetary award for the Fries Prize for Improving Health is $70,000, which will be divided between the recipients.
  • As of 2016, the CDC Foundation manages and administers the Fries Foundation's public health award programs, which include the Fries Prize for Improving Health and the Elizabeth Fries Health Education Award.